Trials / Completed
CompletedNCT03855137
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 778 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atogepant 30 mg | Tablets containing 30 mg atogepant |
| DRUG | Atogepant 60 mg | Tablets containing 60 mg atogepant |
| DRUG | Placebo | 30 mg/60 mg tablets containing atogepant-matching placebo |
Timeline
- Start date
- 2019-03-11
- Primary completion
- 2022-01-20
- Completion
- 2022-01-20
- First posted
- 2019-02-26
- Last updated
- 2023-02-14
- Results posted
- 2023-02-14
Locations
150 sites across 17 countries: United States, Australia, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Poland, Russia, South Korea, Spain, Sweden, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03855137. Inclusion in this directory is not an endorsement.